Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study

Published:2023-06 Issue:6 Volume:23 Page:683-695
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Wong Carlos K H,Lau Kristy T K,Au Ivan C H,Lau Eric H Y,Poon Leo L M,Hung Ivan F N,Cowling Benjamin J,Leung Gabriel M

Funder

Health and Medical Research Fund

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference48 articles.

1. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19;Hammond;N Engl J Med,2022

2. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients;Jayk Bernal;N Engl J Med,2022

3. Nirmatrelvir use and severe COVID-19 outcomes during the omicron surge;Arbel;N Engl J Med,2022

4. Effectiveness of paxlovid in reducing severe COVID-19 and mortality in high risk patients;Najjar-Debbiny;Clin Infect Dis,2022

5. Nirmatrelvir plus ritonavir for early COVID-19 in a large US health system: a population-based cohort study;Dryden-Peterson;Ann Intern Med,2023

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Therapy of SARS-CoV-2 Infection in Children;Journal of Clinical Medicine;2023-12-25

2. Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022;MMWR. Morbidity and Mortality Weekly Report;2023-12-22

3. SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals;MMWR. Morbidity and Mortality Weekly Report;2023-12-22

4. Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation;Nature Communications;2023-12-16

5. Symptoms, Viral Loads, and Rebound Among Coronavirus Disease 2019 (COVID-19) Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated Individuals;Clinical Infectious Diseases;2023-11-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3